With a $130m Series B, the startup is betting that “computer-aided design” can move biologics beyond trial-and-error — and into something closer to software.
In biotech, there is a familiar rhythm to a new “breakthrough”. A flashy chart. A promising molecule. A sentence that begins, “for the first time”. Then come the years: animal studies, manufacturing headaches, clinical trials, regulators, and the uncomfortable truth that biology does not always care about elegance.
Chai Discovery is trying to change that rhythm — not by making better slides, but by trying to make the messy middle of drug discovery behave more like engineering.
